The University of Toronto and McMaster University are joining forces to launch a new $40-million venture capital fund, marking a significant step in the commercialization of Canadian life sciences research. This initiative, managed by Genesys Capital, aims to address the long-standing challenge of Canadian researchers making groundbreaking discoveries while the economic benefits often go abroad. The fund will primarily back spinouts from both universities, focusing on medical devices and drugs targeting cancer and cardiovascular diseases.
This move comes as a response to the underinvestment in domestic life sciences venture capital by Canadian institutional investors. The fund's creation is part of a broader trend, with other universities and organizations also investing in Canadian life sciences startups. The Weston Family's Wittington Innovation Fund, the Terry Fox Foundation, and the Canadian Cancer Agency are among those anchoring similar funds, indicating a growing recognition of the potential for Canadian innovations in the healthcare sector.
The Genesys fund is inspired by successful models from institutions like MIT and the University of California, Berkeley. It represents a significant signal from the universities and the Ontario government about the importance of supporting homegrown innovations. The fund's managers, including Kelly Holman, emphasize the potential for long-term economic growth and societal impact. However, the fund also faces the challenge of competing with the success of similar funds in the United States, where universities like MIT and Stanford University generate substantial licensing revenue from campus inventions.
U of T's President Melanie Woodin and McMaster's President Susan Tighe highlight the importance of early-stage seed funding for Canadian researchers. The universities are investing revenues from their technology transfer offices to support the fund, aiming to bring more innovations to market and benefit Canadians financially and in terms of health and societal impact. The partnership with Genesys Capital, known for its successful track record in launching drug companies, further strengthens the fund's potential for success.
This initiative is a crucial step in changing the narrative of Canadian research commercialization, where the economic benefits of discoveries have often been realized abroad. By anchoring this fund, U of T and McMaster are demonstrating their commitment to supporting their own innovators and contributing to the growth of Canada's life sciences sector.
